162 related articles for article (PubMed ID: 17343986)
21. Emerging drugs in pancreatic cancer.
Ducreux M; Boige V; Malka D
Expert Opin Emerg Drugs; 2004 May; 9(1):73-89. PubMed ID: 15155137
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy in pancreatic adenocarcinoma.
Squadroni M; Fazio N
Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):386-94. PubMed ID: 20496553
[TBL] [Abstract][Full Text] [Related]
23. Icotinib plus gemcitabine for metastatic pancreatic cancer: a case report.
Zhao J; Shen H; Hu HG; Huang JJ
World J Gastroenterol; 2015 Mar; 21(11):3441-6. PubMed ID: 25805958
[TBL] [Abstract][Full Text] [Related]
24. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
Ng SS; Tsao MS; Nicklee T; Hedley DW
Mol Cancer Ther; 2002 Aug; 1(10):777-83. PubMed ID: 12492110
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].
Krempien R; Muenter MW; Huber PE; Nill S; Friess H; Timke C; Didinger B; Buechler P; Heeger S; Herfarth KK; Abdollahi A; Buchler MW; Debus J
BMC Cancer; 2005 Oct; 5():131. PubMed ID: 16219105
[TBL] [Abstract][Full Text] [Related]
26. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Ellenrieder V; König A; Seufferlein T
Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
[TBL] [Abstract][Full Text] [Related]
27. Treatment of metastatic pancreatic adenocarcinoma: a review.
Thota R; Pauff JM; Berlin JD
Oncology (Williston Park); 2014 Jan; 28(1):70-4. PubMed ID: 24683721
[TBL] [Abstract][Full Text] [Related]
28. Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine.
Carmichael J
Digestion; 1997; 58(6):503-7. PubMed ID: 9438594
[TBL] [Abstract][Full Text] [Related]
29. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Baker CH; Solorzano CC; Fidler IJ
Cancer Res; 2002 Apr; 62(7):1996-2003. PubMed ID: 11929816
[TBL] [Abstract][Full Text] [Related]
30. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.
Heinemann V; Reni M; Ychou M; Richel DJ; Macarulla T; Ducreux M
Cancer Treat Rev; 2014 Feb; 40(1):118-28. PubMed ID: 23849556
[TBL] [Abstract][Full Text] [Related]
31. Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis.
Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Barni S
Dig Liver Dis; 2014 May; 46(5):452-9. PubMed ID: 24565950
[TBL] [Abstract][Full Text] [Related]
32. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.
Rivera F; López-Tarruella S; Vega-Villegas ME; Salcedo M
Cancer Treat Rev; 2009 Jun; 35(4):335-9. PubMed ID: 19131170
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.
Yip D; Karapetis C; Strickland A; Steer CB; Goldstein D
Cochrane Database Syst Rev; 2006 Jul; (3):CD002093. PubMed ID: 16855985
[TBL] [Abstract][Full Text] [Related]
34. Treatment of metastatic pancreatic cancer.
Ko AH; Tempero MA
J Natl Compr Canc Netw; 2005 Sep; 3(5):627-36. PubMed ID: 16194454
[TBL] [Abstract][Full Text] [Related]
35. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
[TBL] [Abstract][Full Text] [Related]
36. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.
Borazanci E; Von Hoff DD
Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):739-47. PubMed ID: 24882381
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
Morizane C; Okusaka T; Furuse J; Ishii H; Ueno H; Ikeda M; Nakachi K; Najima M; Ogura T; Suzuki E
Cancer Chemother Pharmacol; 2009 Jan; 63(2):313-9. PubMed ID: 18398614
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
[TBL] [Abstract][Full Text] [Related]
39. Advanced stage pancreatic cancer: novel therapeutic options.
Saif MW
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):487-98. PubMed ID: 24939470
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]